PMID- 23697980 OWN - NLM STAT- MEDLINE DCOM- 20140410 LR - 20211203 IS - 1521-0669 (Electronic) IS - 0888-0018 (Linking) VI - 30 IP - 7 DP - 2013 Oct TI - The mTOR signaling pathway in pediatric neuroblastoma. PG - 605-15 LID - 10.3109/08880018.2013.798058 [doi] AB - Neuroblastoma (NB) is the most common extracranial malignant solid tumors of childhood, and the majority of these high-risk tumors is resistant to nearly all the treatments and has a significantly worse outcome. The mammalian target of rapamycin (mTOR) plays a critical role in oncogenesis and cancer progression of many tumors. This review will describe the function of mTOR, its genetic regulation in pediatric neuroblastoma, and its value as a target for inhibition by anticancer agents for patients with NB. FAU - Mei, Hong AU - Mei H AD - 1Department of Pediatric Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. FAU - Wang, Ye AU - Wang Y FAU - Lin, Zhenyu AU - Lin Z FAU - Tong, Qiangsong AU - Tong Q LA - eng PT - Journal Article PT - Review DEP - 20130522 PL - England TA - Pediatr Hematol Oncol JT - Pediatric hematology and oncology JID - 8700164 RN - 0 (Antineoplastic Agents) RN - 0 (Neoplasm Proteins) RN - EC 2.7.1.1 (MTOR protein, human) RN - EC 2.7.11.1 (TOR Serine-Threonine Kinases) SB - IM MH - Adolescent MH - Antineoplastic Agents/therapeutic use MH - Child MH - Child, Preschool MH - Drug Delivery Systems/methods MH - Female MH - Humans MH - Infant MH - Male MH - Neoplasm Proteins/genetics/*metabolism MH - Neuroblastoma/drug therapy/genetics/*metabolism/pathology MH - *Signal Transduction MH - TOR Serine-Threonine Kinases/genetics/*metabolism EDAT- 2013/05/24 06:00 MHDA- 2014/04/11 06:00 CRDT- 2013/05/24 06:00 PHST- 2013/05/24 06:00 [entrez] PHST- 2013/05/24 06:00 [pubmed] PHST- 2014/04/11 06:00 [medline] AID - 10.3109/08880018.2013.798058 [doi] PST - ppublish SO - Pediatr Hematol Oncol. 2013 Oct;30(7):605-15. doi: 10.3109/08880018.2013.798058. Epub 2013 May 22.